ES2135046T3 - 2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos. - Google Patents

2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos.

Info

Publication number
ES2135046T3
ES2135046T3 ES95912197T ES95912197T ES2135046T3 ES 2135046 T3 ES2135046 T3 ES 2135046T3 ES 95912197 T ES95912197 T ES 95912197T ES 95912197 T ES95912197 T ES 95912197T ES 2135046 T3 ES2135046 T3 ES 2135046T3
Authority
ES
Spain
Prior art keywords
medicines
trisustituted
disstituted
isoxazolines
isoxazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95912197T
Other languages
English (en)
Inventor
Wilfried Schwab
Hiristo Anagnostopulos
Robert Ryder Bartlett
Rudolf Schleyerbach
Klaus Ulrich Weithmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2135046T3 publication Critical patent/ES2135046T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/50—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C205/51—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

UN COMPUESTO DE FORMULA (I) Y/O UNA SAL FISIOLOGICAMENTE ACEPTABLE DEL COMPUESTO DE FORMULA (I) Y/O UNA FORMA ESTEREOISOMERICA DEL COMPUESTO DE FORMULA (I), EN DONDE UN RADICAL R{SUP,1} O R{SUP,2} TIENE EL SIGNIFICADO DE FORMULA (II), ESTA INDICADO PARA LA OBTENCION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFLAMACIONES, ASMA, ENFERMEDADES REUMATICAS Y ENFERMEDADES AUTOINMUNES.
ES95912197T 1994-03-10 1995-03-03 2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos. Expired - Lifetime ES2135046T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4408084A DE4408084A1 (de) 1994-03-10 1994-03-10 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

Publications (1)

Publication Number Publication Date
ES2135046T3 true ES2135046T3 (es) 1999-10-16

Family

ID=6512412

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95912197T Expired - Lifetime ES2135046T3 (es) 1994-03-10 1995-03-03 2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos.

Country Status (17)

Country Link
US (1) US5814627A (es)
EP (1) EP0749429B1 (es)
JP (1) JPH09509951A (es)
KR (1) KR100330798B1 (es)
CN (1) CN1056836C (es)
AT (1) ATE181733T1 (es)
AU (1) AU684914B2 (es)
CA (1) CA2185004A1 (es)
DE (2) DE4408084A1 (es)
DK (1) DK0749429T3 (es)
ES (1) ES2135046T3 (es)
FI (1) FI963508L (es)
GR (1) GR3031266T3 (es)
HU (1) HU225499B1 (es)
NO (1) NO306723B1 (es)
TW (1) TW419469B (es)
WO (1) WO1995024397A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510361A (en) * 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents
AR029304A1 (es) * 1998-06-26 2003-06-25 Daiichi Seiyaku Co DERIVADOS DE PROPIONILO SUSTITUIDOS, PRODUCTO FARMACEUTICO, USO PARA LA FABRICACION DE UNA COMPOSICION FARMACEUTICA PARA LA PREVENCION Y/O TRATAMIENTO DE HIPERCOLESTEROLEMIA, HIPERLIPEMIA O ARTERIOESCLEROSIS, COMPOSICIoN FARMACÉUTICA Y COMPUESTOS INTERMEDIARIOS
WO2000007996A2 (en) 1998-08-07 2000-02-17 Chiron Corporation Pyrazoles as estrogen receptor modulators
USRE39708E1 (en) 1998-08-07 2007-06-26 Chiron Corporation Estrogen receptor modulators
EP1102755B1 (en) * 1998-08-07 2006-01-04 Chiron Corporation Substituted isoxazole derivatives as estrogen receptor modulators
JP2002527438A (ja) * 1998-10-09 2002-08-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４，５−ジヒドロ−イソオキサゾール誘導体及びそれらの製薬学的使用
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
US6579880B2 (en) 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
CA2429426A1 (en) * 2000-11-17 2002-05-23 Takeda Chemical Industries, Ltd. Isoxazole derivatives
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
HRP20050168A2 (en) * 2002-08-23 2005-10-31 Rigel Pharmaceuticals Pyridyl substituted heterocycles useful for treating or preventing hcv infection
WO2004099164A1 (en) 2003-05-02 2004-11-18 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating hcv infection
US7326790B2 (en) * 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
US7220745B2 (en) 2003-05-15 2007-05-22 Rigel Pharmaceuticals Heterocyclic compounds useful to treat HCV
US7807696B2 (en) * 2003-10-07 2010-10-05 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
US7514434B2 (en) 2004-02-23 2009-04-07 Rigel Pharmaceuticals, Inc. Heterocyclic compounds having an oxadiazole moiety and hydro isomers thereof
CN101768129B (zh) 2004-03-05 2012-05-23 日产化学工业株式会社 异*唑啉取代苯甲酰胺化合物的制备中间体
WO2005097760A1 (en) * 2004-03-26 2005-10-20 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
CA2606106A1 (en) * 2005-05-02 2007-03-08 Rigel Pharmaceuticals, Inc. Heterocyclic anti-viral compounds comprising metabolizable moieties and their uses
DK2797899T3 (en) * 2011-12-27 2016-04-04 Bayer Ip Gmbh Heteroarylpiperidin and -piperazinderivater as fungicides
BR122015019867A2 (pt) 2013-01-14 2019-08-27 Kraton Polymers Us Llc processo para preparar um copolímero de bloco funcionalizado em amino
TW202502311A (zh) * 2023-03-29 2025-01-16 美商默沙東有限責任公司 Il4i1抑制劑及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58148858A (ja) * 1982-02-26 1983-09-05 Yamanouchi Pharmaceut Co Ltd ３，５−ジ−ｔｅｒｔ−ブチル−４−ヒドロキシフエニル置換複素環化合物
IE59813B1 (en) * 1986-05-09 1994-04-06 Warner Lambert Co Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them
US5086064A (en) * 1990-03-27 1992-02-04 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl thiazolyl, oxazolyl, and imidazolyl methanones and related compounds as antiinflammatory agents
US5510361A (en) * 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents

Also Published As

Publication number Publication date
CN1056836C (zh) 2000-09-27
TW419469B (en) 2001-01-21
ATE181733T1 (de) 1999-07-15
CN1143956A (zh) 1997-02-26
WO1995024397A1 (de) 1995-09-14
CA2185004A1 (en) 1995-09-14
EP0749429A1 (de) 1996-12-27
US5814627A (en) 1998-09-29
NO963560L (no) 1996-08-26
DE59506310D1 (de) 1999-08-05
HU9602458D0 (en) 1996-11-28
NO306723B1 (no) 1999-12-13
DK0749429T3 (da) 2000-01-10
FI963508A0 (fi) 1996-09-06
JPH09509951A (ja) 1997-10-07
HU225499B1 (en) 2007-01-29
AU1948195A (en) 1995-09-25
FI963508A7 (fi) 1996-09-06
KR970701703A (ko) 1997-04-12
DE4408084A1 (de) 1995-09-14
HUT76481A (en) 1997-09-29
GR3031266T3 (en) 1999-12-31
AU684914B2 (en) 1998-01-08
FI963508L (fi) 1996-09-06
EP0749429B1 (de) 1999-06-30
KR100330798B1 (ko) 2002-10-11

Similar Documents

Publication Publication Date Title
ES2135046T3 (es) 2-isoxazolinas e isoxazoles 3,5-disustituidos y 3,4,5-trisustituidos, procedimiento para su preparacion y su empleo como medicamentos.
IL178072A0 (en) Use of monoesters of probucol or a pharmaceutically acceptable salt thereof for preparing medicaments for the treatment of cardiovascular disease
ATE69376T1 (de) Haarwuchsmittel.
ES2145922T3 (es) Compuestos espiro-azabiciclicos utiles en terapia.
KR930702026A (ko) 자기항원의 경구 투여에 의한 자기면역 질병의 치료
MX9701385A (es) Preparacion de producto combinado para usarse en enfermedades inmunologicas.
ES2192839T3 (es) Timosina beta 4 oxidada.
ES2069755T3 (es) Preparacion de glutationa en aerosol y metodo para aumentar el nivel de glutationa en los pulmones.
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
ES2143132T3 (es) Monohidratos de derivado de acido aminobenceno-sulfonico y su metodo de preparacion.
ES2068705T3 (es) Tratamiento de la enfermedad neoplastica con interleuquina-10.
GR3005768T3 (es)
BRPI0107493B8 (pt) substâncias para uso no tratamento de psoríase
CA2256514A1 (en) Veterinary use of a pleuromutilin derivative
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
MX26167A (es) Derivados de acido piridil-benzoico para el tratamiento de enfermedades relacionadas con lecotrino.
IT8721115A0 (it) Fitopreparato per la cura di affezioni cutanee.
BR9607996A (pt) Derivado de aminotetralina para o tratamento de doenças cardiovasculares
KR930702990A (ko) 섬유성 질병 치료제로서의 프로스타사이클린- 및 카르바사이클린 유도체
ES2124926T3 (es) Uso de desoxipergualina para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias e hiperreactivas.
IL101163A (en) Use of flunarizine in the preparation of medicaments for treating neoplastic diseases
LV11524A (lv) Benzidamina izmantosana TNF izsaukto patologisko stavoklu arstesana
MX9203205A (es) Novedosos acidos dimetilamino-hidroxi-alcan-difosfonicos y sales de los mismos, en procedimiento de produccion y composiciones farmaceuticas relacionadas.
PT89582A (pt) Processo para a preparacao de antibioticos beta-lactamicos uteis como medicamentos
ES2167942T3 (es) Empleo de 2-aminotetralinas 6,7-sustituidas apropiadas para la preparacion de una composicion farmaceutica para el tratamiento terapeutico de patologias inflamatorias y/o autoinmunes.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 749429

Country of ref document: ES